The Comparative Study Showing of the Effect of Telmisartan and Ramipril on Diabetic Profile in Hypertensive Pre-Diabetic Patients | Chapter 10 | Technological Innovation in Pharmaceutical Research Vol. 8

 Background: Hypertension, a prevalent cardiovascular disease, is rapidly being linked to other co-morbid disorders such as diabetes mellitus, which worsens its prognosis. Telmisartan and ramipril are both antihypertensive medications. The efficacy of telmisartan and ramipril in managing or avoiding the progression of pre-diabetes to diabetes in stage 1 hypertension patients is compared in this study. It also seeks to compare the effects of Telmisartan and Ramipril on FBS and HbA1C in males and females across a 12-month treatment period.

Methods: A 12-month prospective, randomised, single-center, comparative observational study on stage 1 hypertension patients with pre-diabetes is done. A total of 60 individuals are enlisted and assigned to one of two therapy groups. They were given the designated medicine for a 12-month period and were followed up on. Blood pressure was taken and a diabetes profile was checked at each appointment.

The results of this study demonstrated that both telmisartan and ramipril efficiently regulated blood pressure. In stage 1 hypertension individuals with pre diabetes, telmisartan reduced the progression of fasting blood sugar and glycosylated haemoglobin better than ramipril.

Conclusions: Both telmisartan and ramipril had an effect on blood pressure regulation. In stage 1 hypertension patients with pre diabetes, telmisartan has a statistically significant benefit in delaying the progression of prediabetes to diabetes mellitus when compared to ramipril.

Author (s) Details

Abdullah Ansari
Department of Pharmacology, Ayaan Institute of Medical Sciences, Moinabad, Telangana, India.

Ayesha Raoof
Department of Medicine, HAL Medical Centre, Hyderabad, Telangana, India.

View Book :- https://stm.bookpi.org/TIPR-V8/article/view/2213